Redx to Present RXC004 Phase 1 Combination Data

REDX PHARMA PLC

("Redx" or "the Company")

Redx to Present a Poster on Phase 1 Clinical Data for the Combination Arm of the RXC004 Clinical Study at Society for Immunotherapy of Cancer Conference

Alderley Park, UK, 3 November 2022 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that it will present a poster on the combination module of the Phase 1 clinical study (clinicaltrials.gov NCT03447470) of RXC004 at the Society for Immunotherapy of Cancer (SITC) Conference (8-12 November 2022, Boston, MA).

The poster will present results from the combination module of the Phase 1 clinical study in which RXC004 was combined with nivolumab, an anti-PD-1 antibody, in patients with advanced solid tumours. RXC004 is a clinical stage, highly potent and selective, orally active Porcupine inhibitor being developed as a targeted therapy for Wnt-ligand dependent cancer.

RXC004 is currently being evaluated in two Phase 2 proof-of-concept clinical studies in genetically selected metastatic colorectal cancer (mCRC) (clinicaltrials.gov NCT04907539), and in biliary tract cancers and genetically selected pancreatic cancer (clinicaltrials.gov NCT04907851). Following the completion of this Phase 1 combination study, the Company will now initiate enrolment into combination cohorts of RXC004 with anti-PD-1 antibodies in mCRC and biliary tract cancers, within these Phase 2 studies.

A copy of the poster will be made available on the Company's website following the presentation at: https://www.redxpharma.com/scientific-publications/ 

About Redx Pharma Plc 

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is currently in pre-IND stage, with Phase 1 clinical studies expected to commence in 2023. 

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a preclinical pan-RAF inhibitor which has received IND clearance from the US FDA, and an early stage oncology research collaboration.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/